ADAGENE
Adagene is a clinical-stage biotech company that specializes in developing immuno-oncology antibodies against novel epitopes. It has its proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody.
ADAGENE
Industry:
Biotechnology Medical Oncology Therapeutics
Founded:
2011-01-01
Address:
Suzhou, Jiangsu, China
Country:
China
Website Url:
http://www.adagene.com
Total Employee:
51+
Status:
Active
Contact:
+051287773632
Email Addresses:
[email protected]
Total Funding:
155 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Google Font API Google Tag Manager WordPress Google Analytics Amazon SSL By Default
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Alphamab Oncology
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization.
Arcturus Therapeutics
Arcturus Therapeutics is a clinical-stage company specializing in mRNA medicines and vaccines.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Innolake Biopharm
Innolake Biopharm clinical-stage biotech company with a focus on oncology and autoimmune disease areas.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
TOT BIOPHARM
TOT BIOPHARM is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs.
Trymed
Trymed is a clinical research company that seeks new treatments in oncology and other therapeutic areas.
Current Advisors List
Current Employees Featured
Stock Details
Investors List
F-Prime Capital
F-Prime Capital investment in Series D - Adagene
Eight Roads Ventures
Eight Roads Ventures investment in Series D - Adagene
Wuxi Venture Capital Group
Wuxi Venture Capital Group investment in Series D - Adagene
General Atlantic
General Atlantic investment in Series D - Adagene
Sequoia Capital China
Sequoia Capital China investment in Series D - Adagene
Gopher Asset Management
Gopher Asset Management investment in Series C - Adagene
New World TMT Ltd
New World TMT Ltd investment in Series C - Adagene
AVIC Trust
AVIC Trust investment in Series C - Adagene
Sequoia Capital China
Sequoia Capital China investment in Series C - Adagene
King Star Capital
King Star Capital investment in Series C - Adagene
Key Employee Changes
| Date | New article |
|---|---|
| 2021-08-12 | Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board |
Official Site Inspections
http://www.adagene.com Semrush global rank: 5.07 M Semrush visits lastest month: 1.59 K
- Host name: ec2-52-10-106-184.us-west-2.compute.amazonaws.com
- IP address: 52.10.106.184
- Location: Boardman United States
- Latitude: 45.8491
- Longitude: -119.7143
- Metro Code: 810
- Timezone: America/Los_Angeles
- Postal: 97818
More informations about "Adagene"
Company Overview - Adagene
Our discovery engine, Dynamic Precision Library, is driving Adageneโs pipeline of programs with potential to be first or best in class. We have forged strategic partnerships with multiple reputable global companies. These partnerships โฆSee details»
Adagene - Crunchbase Company Profile & Funding
Adagene is a clinical-stage biotech company that specializes in developing immuno-oncology antibodies against novel epitopes. It has its proprietary Smart Antibody Technology, which โฆSee details»
Investor Relations โ Adagene Inc.
Feb 27, 2025 Adagene (NASDAQ: ADAG) is a publicly traded, global, clinical-stage biopharmaceutical company committed to transforming the discovery and development of โฆSee details»
Adagene - LinkedIn
Adagene Inc. (Nasdaq: ADAG) is a biotechnology company transforming the discovery and development of novel antibody-based cancer immunotherapies.See details»
Adagene Inc. (ADAG) Company Profile & Facts - Yahoo Finance
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates โฆSee details»
Careers - Adagene
Adagene is an equal opportunity employer that is committed to diversity and inclusion. We prohibit discrimination and harassment of any kind based on race, color, religion, sex, sexual โฆSee details»
Adagene - Funding, Financials, Valuation & Investors - Crunchbase
Adagene is registered under the ticker NASDAQ:ADAG . Their stock opened with $19.00 in its Feb 9, 2021 IPO. Adagene is funded by 11 investors. ... How much funding has this โฆSee details»
Adagene Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Adagene has 5 employees across 3 locations and $18.11 m in annual revenue in FY 2023. See insights on Adagene including office locations, competitors, revenue, financials, โฆSee details»
Adagene Reports Full Year 2024 Financial Results and Provides โฆ
5 days ago Wang has served on Adageneโs Board since 2023 and provided invaluable guidance as Adagene has developed ADG126 through first-in-human clinical trials. Mervyn Turner , โฆSee details»
Adagene - Contacts, Employees, Board Members, Advisors & Alumni
Adagene is a clinical-stage biotech company that specializes in developing immuno-oncology antibodies. New. Resources. ... Experience the new Crunchbase, powered by AI . Experience โฆSee details»
Adagene, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Feb 25, 2025 Adageneโs lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor โฆSee details»
Adagene - Overview, News & Similar companies | ZoomInfo.com
Adagene is a clinical stage biotech company with innovative antibody discovery and engineering technologies. This company develops immuno-oncology antibodies against novel epitopes that โฆSee details»
Company Adagene Inc. BOERSE MUENCHEN - MarketScreener.com
Feb 27, 2025 Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer โฆSee details»
About - Adagene
Toggle navigation. ็ฎไฝไธญๆ. English; ็ฎไฝไธญๆSee details»
News Releases - Adagene Inc.
Jan 27, 2025 Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO โฆSee details»
Company Adagene Inc. - MarketScreener.com
Jan 31, 2018 Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer โฆSee details»
Adagene Reports Full Year 2024 Financial Results and Provides โฆ
4 days ago Net loss attributable to Adagene Inc.โs shareholders (18,946,370 ) (33,424,111 ) Other comprehensive income (loss) Foreign currency translation adjustments, net of nil tax โฆSee details»
SAFEbody - Adagene
SAFEbody ® is our proprietary precision antibody masking platform designed to enable an antibody to bind its target specifically only after conditional activation of the antibody in target โฆSee details»
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 โฆ
Jul 12, 2024 Adageneโs lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor โฆSee details»
Adagene Reports Full Year 2024 Financial Results and Provides โฆ
3 days ago SAN DIEGO, SUZHOU, China - Adagene Inc. (' Adagene ') (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and โฆSee details»